COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,617 Articles (22,913 medRxiv, 8,704 bioRxiv)

Most recent first Previous |  Page 1667: Articles 16661-16670  | Next

Social, demographic and behavioural determinants of SARS-CoV-2 infection: A case-control study carried out during mass community testing of asymptomatic individuals in South Wales, December 2020
Thomas, D. R., Fina, L., Adamson, J., Sawyer, C., Jones, A., Nnoaham, K., Barrasa, A., Shankar, G., Williams, C.
10.1101/2021.04.06.21253465 — Posted: 2021-04-09
Characterising contact in disease outbreaks via a network model of spatial-temporal proximity
Myall, A. C., Peach, R. L., Wan, Y., Mookerjee, S., Jauneikaite, E., Bolt, F., Price, J. R., Davies, F., Wiesse, A. Y., Holmes, A., Barahona, M.
10.1101/2021.04.07.21254497 — Posted: 2021-04-09
Correcting COVID-19 PCR Prevalence for False Positives in the Presence of Vaccination Immunity
Halem, M.
10.1101/2021.04.06.21255029 — Posted: 2021-04-09
Continuous monitoring of SARS-CoV-2 RNA in urban wastewater from Porto, Portugal: sampling and analysis protocols
Tomasino, M. P., Semedo, M., Vieira, P., Ferraz, E., Rocha, A., Carvalho, M. F., Magalhaes, C., Mucha, A. P.
10.1101/2021.04.06.21254994 — Posted: 2021-04-09
The Value of a Regional Living COVID-19 Registry and the Challenges of Keeping It Alive
Hanna, J., Chen, T., Portales-Castillo, C., Newhart, D., Schantz, K., Rozzi, K., Bress, J., Lesho, E.
10.1101/2021.04.06.21255019 — Posted: 2021-04-09
Performance Comparison of a Flow Cytometry-based and Two Commercial Chemiluminescent Immunoassays for Detection and Quantification of Antibodies Binding to SARS-CoV-2 Spike Protein
Valdivia, A., Tarin, F., Alcaraz, M. J., Pinero, P., Torres, I., Marco, F., Albert, E., Navarro, D.
10.1101/2021.04.06.21254995 — Posted: 2021-04-09
Short-range exposure to airborne virus transmission and current guidelines
Wang, J., Alipour, M., Soligo, G., Roccon, A., De Paoli, M., Picano, F., Soldati, A.
10.1101/2021.04.06.21255017 — Posted: 2021-04-09
Improved diagnosis of SARS-CoV-2 by using Nucleoprotein and Spike protein fragment 2 in quantitative dual ELISA tests
De Marco Verissimo, C., O'Brien, C., Lopez Corrales, J., Dorey, A., Cwiklinski, K., Lalor, R., Doyle, J. M., Field, S., Masterson, C., Ribes Martinez, E., Hughes, G., Bergin, C., Walshe, K., McNicholas, B., Laffey, J., Dalton, J. P., Kerr, C., Doyle, S.
10.1101/2021.04.07.21255024 — Posted: 2021-04-09
Statistical Design and Analysis of PCR Tests for Fast Mutating Viruses
Han, Y., Sun, Y., Hsu, J. C., House, T., Gent, N., Hall, I.
10.1101/2021.04.07.21254917 — Posted: 2021-04-09
TCA-soluble blood serum proteins of COVID-19 patients as possible predictive markers for the disease severity
Orfin, A., Alexanyan, T., Svitlana Tkachuk, S. T., Starodub, A., Luchyshyn, T., Sibirny, A., Souchelnytskyi, S., Kit, Y.
10.1101/2021.04.07.21255063 — Posted: 2021-04-09

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).